The Surprising FDA View That Sent Moderna Stock Flying
Moderna stock prices increased following positive feedback from the FDA regarding the company's mRNA influenza vaccine candidate.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has released a review appearing to align with Moderna's development of an mRNA-based influenza vaccine. This development coincides with reports that the technology expands B cell response breadth and provides protection against a diverse range of influenza strains.
Coverage from Fierce Biotech, BioSpace, and Investor's Business Daily emphasizes the current alignment between regulators and the company. Nature and Medical Xpress provide the underlying scientific context regarding the vaccine's ability to trigger broader human immune responses.
Market participants are monitoring the upcoming advisory committee meeting. Coverage does not yet specify the exact date of the adcomm grilling or the specific metrics of the stock price movement.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 151d ago.
Quick answers
Why did Moderna stock rise?
Investor's Business Daily reports the increase followed a favorable review from the FDA concerning the company's mRNA flu vaccine.
What does the science say about the vaccine?
According to Nature and Medical Xpress, the vaccine has shown potential to expand the breadth of human B cell responses and offer protection against diverse influenza strains.
What is the next step for the vaccine?
Fierce Biotech and BioSpace indicate that an advisory committee review is the next significant event.
Coverage (10)
- MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns Yahoo Finance · 151d ago
- Quick takes: Moderna mRNA flu vaccine review, NIH award for genital herpes vaccine, malaria monoclonal antibody trial CIDRAP · 151d ago
- FDA appears open to Moderna’s flu vaccine ahead of adcomm statnews.com · 151d ago
- Moderna flu shot data may support use in older adults, US FDA staff says Reuters · 151d ago
- Why Is Moderna (MRNA) Stock Soaring Today Yahoo Finance · 151d ago
- Amenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling Fierce Biotech · 151d ago
- mRNA-based influenza vaccine expands the B cell response breadth in humans Nature · 151d ago
- mRNA flu vaccine offers immune protection against diverse strains Medical Xpress · 151d ago
- FDA, Moderna appear aligned on mRNA flu shot heading into adcomm BioSpace · 151d ago
- The Surprising FDA View That Sent Moderna Stock Flying Investor's Business Daily · 151d ago
Topics
Related trends
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
The US flu season is off to a very early start. It’s targeting the South and West now
The U.S. flu season has started earlier than usual with elevated activity concentrated in the South and West, and the CDC reports five pediatric deaths so far this season.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Dallas County child dies from the flu - FOX 4 News Dallas-Fort Worth
Dallas County records its first pediatric flu death since 2022 as the 2026-27 season begins.
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'
Here's why North Texas is experiencing an earlier flu season
An earlier-than-usual arrival of the flu season prompts surges, rising ER visits, and vaccination warnings across multiple states.